A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors.
第一作者:
Zhuang,Kang
第一单位:
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
作者:
主题词
人类(Humans);女(雌)性(Female);血管内皮生长因子A(Vascular Endothelial Growth Factor A);肿瘤复发, 局部(Neoplasm Recurrence, Local);肿瘤(Neoplasms);神经胶质瘤(Glioma);受体, 集落刺激因子(Receptors, Colony-Stimulating Factor);高血压(Hypertension);最大耐受剂量(Maximum Tolerated Dose)
DOI
10.1007/s10637-022-01325-4
PMID
36884148
发布时间
2023-05-12
- 浏览1

Investigational new drugs
296-305页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文